一个意想不到的现象:一种由西塔洛普拉姆诱导的运动障碍病例
Fabienne J Jean1, Michael Poulose2
1Neurology, Touro College of Osteopathic Medicine, New York City, USA.
Cureus
|July 1, 2024
概括
选择性血清素再吸收抑制剂 (SSRI) 可以通过间接的多巴胺D2受体阻塞引起异动运动,一种超动运动. 这一案例突出了SSRI潜在的外皮拉米德副作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 功能失调的运动是超动态的,重复的运动与多巴胺D2受体阻塞有关.
- 与抗精神病药物一样,多巴胺受体阻断剂 (DRBA) 是常见的原因.
- 选择性血清素再吸收抑制剂 (SSRI) 很少会诱导运动障碍.
研究的目的:
- 报告在短时间内服用西塔洛普拉姆 (一种SSRI) 后出现急性运动障碍的情况.
- 为了提高人们对与SSRI使用相关的潜在外皮拉米德副作用 (EPS) 的认识.
主要方法:
- 病例报告详细介绍了一名患有脑的患者,他发展了动力障碍的运动.
- 通过间接的多巴胺D2受体阻断进行SSRI诱导的动力障碍的拟议机制的审查.
主要成果:
- 患者在短时间的西塔洛普拉姆治疗后表现出急性运动障碍.
- 观察到的运动模仿了通常与多巴胺受体阻断剂 (DRBAs) 观察到的运动.
结论:
- 包括西塔洛普拉姆在内的SSRI可能会作为额外金字塔的副作用导致运动障碍.
- 临床医生应考虑在出现这些症状的患者中考虑SSRI诱导的动力障碍,特别是那些有先前存在的神经疾病的患者.
关键词:
药物不良反应 药物不良反应抗抑郁药是一种抗抑郁药.对于citalopram来说,这是一个很好的选择.多巴胺受体阻断剂是多巴胺受体阻断剂.运动障碍症 运动障碍症运动障碍和震.神经学 神经学 神经学选择性血清素受体抑制剂 (SSRI) 的使用.由于SSRI诱发了额外金字塔的症状.更多相关视频
相关概念视频
Parkinson's Disease: Treatment
254
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
254
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
120
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
120
Antiepileptic Drugs: Potassium Channel Activators
168
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
168
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
244
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
244
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
363
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
363
Antidepressant Drugs: MAOIs and Other Agents
215
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
215


